Scarica l'app Stockscreener
13.35
4.64%
-0.65
Dopo l'orario di chiusura:
13.41
0.06
+0.45%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$14.00
Aprire:
$13.61
Volume 24 ore:
9.74M
Relative Volume:
1.95
Capitalizzazione di mercato:
$10.65B
Reddito:
$220.00K
Utile/perdita netta:
$-1.21B
Rapporto P/E:
-8.3235
EPS:
-1.6039
Flusso di cassa netto:
$-387.48M
1 W Prestazione:
-4.37%
1M Prestazione:
-13.70%
6M Prestazione:
-10.76%
1 anno Prestazione:
-49.53%
Intervallo 1D:
$12.99
$13.71
Intervallo di 1 settimana:
$12.99
$15.75
Portata 52W:
$12.25
$30.05
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
13.35 | 12.05B | 220.00K | -1.21B | -387.48M | -1.6039 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Iniziato | Stifel | Buy |
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Underweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Summit Therapeutics (NASDAQ:SMMT) Shares Down 4.7%Here's Why - MarketBeat
Dimensional Fund Advisors LP Sells 288,067 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard? - Yahoo Finance
Summit Therapeutics Inc. (SMMT) stock price, news, quote and history - Yahoo Finance Singapore
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $28.34, Implies 88% Upside - TradingView
Summit Therapeutics (SMMT) Stock Gains on China Label Expansion for Ivonescimab - GuruFocus
Summit lead drug granted China label expansion (SMMT:NASDAQ) - Seeking Alpha
Can Summit Therapeutics (NASDAQ:SMMT) Extend Its Momentum? - Kalkine Media
Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC - marketscreener.com
Summit Therapeutics (NASDAQ:SMMT) Upgraded at Leerink Partners - MarketBeat
Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12 - marketscreener.com
Summit Therapeutics (NASDAQ:SMMT) Stock Price Crosses Above 50-Day Moving AverageTime to Sell? - MarketBeat
Why Is SMMT Stock Tumbling Today? - Stocktwits
Summit Therapeutics Inc (SMMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Did Expanding Ivonescimab Into First-Line Bladder Cancer Just Shift Summit Therapeutics' (SMMT) Investment Narrative? - Sahm
Lowey Dannenberg, P.C. is Investigating Summit Therapeutics - GlobeNewswire
Ivonescimab Expands Into First-Line Bladder Cancer – Summit Therapeutics - Oncodaily
Summit Therapeutics (SMMT) Launches Global Phase II/III Trial fo - GuruFocus
Summit TherapeuticsInitiates Global Phase Ii/Iii Harmoni-Gu1 Trial Of Ivonescimab In Bladder Cancer - TradingView
Summit Therapeutics (NASDAQ: SMMT) launches Phase II/III HARMONi-GU1 bladder cancer study - Stock Titan
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer - Business Wire
Jim Cramer Stock Picks: Summit Therapeutics Is A 'Great Spec'Carvana (NYSE:CVNA) - benzinga.com
The Manufacturers Life Insurance Company Has $11.24 Million Stake in Summit Therapeutics PLC $SMMT - MarketBeat
Clear Street Keeps Their Buy Rating on Summit Therapeutics (SMMT) - The Globe and Mail
Summit Therapeutics Inc. (SMMT) Investor Outlook: Exploring A Potential 117.69% Upside - DirectorsTalk Interviews
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of "Hold" from Analysts - MarketBeat
Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches (SMMT) - Seeking Alpha
Summit Therapeutics (SMMT) Is Down 13.2% After Equity Offering And Ivonescimab Updates Has The Bull Case Changed? - Sahm
Summit Therapeutics Reports Q2 2026 Financial Results and Major Clinical Progress for Ivonescimab - Oncodaily
Summit Therapeutics stock hits 52-week low at 12.52 USD By Investing.com - Investing.com Canada
SMMT|Summit Therapeutics Inc|Price:13.105|Chg%:-0.555 - TradingKey
Summit Therapeutics Inc (SMMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm - Morningstar
Summit Therapeutics Inc (SMMT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Summit Therapeutics Inc (SMMT) Cash Flow - TradingKey
Summit Therapeutics officers investigated for p... - Pluang
Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring a 105.67% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Summit Therapeutics Faces Serious Going-Concern Risk as Cash Shortfall Threatens Operations - The Globe and Mail
Piper Sandler Keeps Their Hold Rating on Summit Therapeutics (SMMT) - The Globe and Mail
SMMT|Summit Therapeutics Inc|Price:13.660|Chg%:-1.320 - TradingKey
Summit Therapeutics (SMMT) Analyst Maintains Neutral Rating Afte - GuruFocus
SMMT Maintained by Guggenheim -- Price Target Lowered to $38.00 - GuruFocus
SMMT Maintained by Stifel -- Price Target Lowered to $38.00 - GuruFocus
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $29.06, Implies 94% Upside - TradingView
Summit Therapeutics Establishes $380 Million ATM Equity Program - The Globe and Mail
Jefferies Cuts Summit Therapeutics Price Target to $15 From $17, Hold Rating Kept - marketscreener.com
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $29.2, Implies 95% Upside - TradingView
SMMT Stock Heads For Third Straight Weekly Drop – Analyst Tempers Expectations From Initial Lung Cancer Trial Survival Data - Stocktwits
Summit Therapeutics Flags Going Concern Risk Over Cash Needs - Benzinga
Summit Therapeutics Inc. Revenue Breakdown – NASDAQ:SMMT - TradingView
Stifel cuts Summit Therapeutics stock price target on timing concerns By Investing.com - Investing.com Canada
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):